Nanochon, a cultivate(MD) portfolio company developing an implant for treating articular cartilage defects in the knee, has secured commitments to close an oversubscribed funding round, bringing its total capital raised to date to $11.3 million. The round was led by cultivate (MD), with significant contributions from The University of Virginia UVA Seed Fund, WSGR, Wealthing […]
Nanochon closes $4.1M Seed Prime II Funding Round Read More »
Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was granted Health Canada approval for their first in human clinical trial. The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with
Nanochon Announces Health Canada Approval for First in Human Investigation Read More »
Nanochon, a cultivate(MD) portfolio company, has launched a new podcast titled “ChonChats,” hosted by Benjamin Holmes and Rachel Offenburg. The inaugural episode features R. Sean Churchill, MD, MBA, discussing:
Dr. Sean Churchill, MBA Joins Nanochon’s ChonChats Read More »
Grand Rapids, Mich., November 27, 2023 — cultivate(MD) Capital Funds LP, funds that are focused on investments into early-stage medical device companies with innovative technologies, announced today that they have made a significant investment into Nanochon, a Washington, D.C.—based regenerative cartilage innovator. Nanochon develops solutions utilized by sports medicine physicians to treat active patients requiring
cultivate(MD) Capital Funds LP Announce Investment into Nanochon Read More »
